Basic Information
Rebif Solution for Injection in Cartridge 22mcg/0.5ml
INJECTION, SOLUTION
Regulatory Information
SIN13974P
June 17, 2011
Prescription Only
Therapeutic
SUBCUTANEOUS
August 10, 2023
June 3, 2025
XL03AB07
Company Information
Active Ingredients
Strength: 22mcg/0.5ml
Detailed Information
Contraindications
**4.3 Contraindications** - Hypersensitivity to natural or recombinant interferon-β, or to any excipients. - Current severe depression and/or suicidal ideation (see sections 4.4 and 4.8 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).
Indication Information
**4.1 Therapeutic indications** Rebif is indicated for the treatment of relapsing multiple sclerosis. In clinical trials, this was characterised by two or more acute exacerbations in the previous two years (see section 5.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). Efficacy has not been demonstrated in patients with secondary progressive multiple sclerosis without ongoing relapse activity (see section 5.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).